Ayurvedic management of Atherogenic Dyslipidemia with Amritadi Guggulu and Phalatrikadi Kwatha along with lifestyle changes

Efficacy of Amritadi Guggulu and Phalatrikadi Kwatha along with lifestyle modification in the management of Atherogenic Dyslipidemia- An open labelled single arm exploratory trial - AD

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/081252

Enrollment

Registered

2025-02-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E782- Mixed hyperlipidemia

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age from 30 to 60 years, irrespective of gender, caste, religion and socioeconomic status. 2. Patient fulfilling diagnostic criteria (According to National Cholesterol Education Program, Adult Treatment Panel III- Sr.Triglycerides above 150 mg/dl, Sr.LDL above 100 mg/dl, Sr.HDL below 40 mg/dl) 3. BMI from 18.5 to 34.9 kg/m2 (Normal, overweight, obese class I) 4. Newly diagnosed cases of Atherogenic Dyslipidemia but not taking any Hypolipidemic drugs and previously diagnosed cases, inspite of taking hypolipidemic drugs fulfilling diagnostic criteria can be selected after giving proper washout period. 5. Patient willing for trial and ready to give written consent.

Exclusion criteria

Exclusion criteria: 1. Age group below 30 years and above 60 years. 2. Lipid profile with very high level (Sr.Triglyceride above 499 mg/dl, Sr.LDL above 190 mg/dl. 3. BMI below 18.5 and above 34.9 kg/m2 4. Patient suffering from type I DM, poorly controlled DM type II (RBS above 200), poorly controlled HTN (Systolic BP above 160 mm of Hg, Diastolic BP above 100 mm of Hg), known cases of Hypothyroidism. 5. Patient with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities. 6. Patients with history of myocardial infraction, stroke or has undergone coronary artery bypass surgery, percutaneous transluminal coronary angioplasty or unstable or severe peripheral artery disease. 7. Drug induced hyperlipidemia (Glucocorticoids, diuretics) 8. Patient suffering from major systemic illness necessitating long term treatment (RA, PTB, malignancy, ARD, CKD) 8. Alcoholic or drug abuse patients. 9. Patient on oral contraceptives, pregnant female or planning for pregnancy, lactating mother.

Design outcomes

Primary

Measure	Time frame
Correction in Lipid profile (Mean reduction in the levels of Sr.Triglycerides and Sr.LDL while increase in Sr.HDL level)Timepoint: 8 weeks	—

Secondary

Measure	Time frame
1. Reduction in BMI. 2. Reduction in Apolipoprotein B. 3. Reduction in the Atherosclerotic Cardiovascular Diseases (ASCVD) risk score and QRISK Score3.Timepoint: 8 weeks	—

Countries

India

Contacts

Public ContactShravani Uday Mahajan

Institute of Teaching and Research in Ayurveda Jamnagar

dhanvantarihcare@yahoo.com9558805421

Outcome results